These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8321845)

  • 1. Theoretical considerations for the design and development of a drug: influence of pharmacokinetics and dosage regimen on receptor interactions.
    Mordenti J; Rescigno A
    Pharm Res; 1993 May; 10(5):777-82. PubMed ID: 8321845
    [No Abstract]   [Full Text] [Related]  

  • 2. [Superaspirin in the platelet aggregation inhibitor therapy].
    Rossi G
    Recenti Prog Med; 1997 Dec; 88(12):590-1. PubMed ID: 9522603
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles.
    Modi NB; Reynolds T; Baughman SA; Thomas DA; Paasch BD; Smith SY
    J Cardiovasc Pharmacol; 1996 Jan; 27(1):105-12. PubMed ID: 8656642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic analysis of antiplatelet effect of sarpogrelate hydrochloride and its application to drug dosage regimen--modeling based on reversible inhibition of 5-HT2 serotonergic receptor in the platelet membrane by sarpogrelate hydrochloride and its metabolite].
    Shimizu T; Yamada Y; Tashita A; Yamamoto K; Kotaki H; Sawada Y; Iga T
    Yakugaku Zasshi; 1999 Nov; 119(11):850-60. PubMed ID: 10590712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.
    Gilchrist IC
    Clin Pharmacokinet; 2003; 42(8):703-20. PubMed ID: 12846593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring receptor target coverage: a radioligand competition binding protocol for assessing the association and dissociation rates of unlabeled compounds.
    Sykes DA; Dowling MR; Charlton SJ
    Curr Protoc Pharmacol; 2010 Sep; Chapter 9():Unit 9.14. PubMed ID: 22294377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties.
    Weiland GA; Molinoff PB
    Life Sci; 1981 Jul; 29(4):313-30. PubMed ID: 6116136
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of TP-9201, a GPIIbIIIa antagonist, in rats and dogs.
    Modi NB; Baughman SA; Paasch BD; Celniker A; Smith SY
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):888-97. PubMed ID: 7564333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of absorption enhancers on the oral absorption of the GP IIB/IIIA receptor antagonist, DMP 728, in rats and dogs.
    Burcham DL; Aungst BA; Hussain M; Gorko MA; Quon CY; Huang SM
    Pharm Res; 1995 Dec; 12(12):2065-70. PubMed ID: 8786991
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
    Mousa SA; DeGrado WF; Mu DX; Kapil RP; Lucchesi BR; Reilly TM
    Circulation; 1996 Feb; 93(3):537-43. PubMed ID: 8565173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of receptor interactions using binding methods.
    Lazareno S
    J Recept Signal Transduct Res; 2001; 21(2-3):139-65. PubMed ID: 11757681
    [No Abstract]   [Full Text] [Related]  

  • 12. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
    Keirns J; Sawamoto T; Holum M; Buell D; Wisemandle W; Alak A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):787-90. PubMed ID: 17116670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome].
    Khaspekova SG; Ziuriaev IT; Iakushkin VV; Golubeva NV; Ruda MIa; Mazurov AV
    Kardiologiia; 2011; 51(7):4-7. PubMed ID: 21878077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic RGD peptide analogues as antiplatelet antithrombotics.
    Barker PL; Bullens S; Bunting S; Burdick DJ; Chan KS; Deisher T; Eigenbrot C; Gadek TR; Gantzos R; Lipari MT
    J Med Chem; 1992 May; 35(11):2040-8. PubMed ID: 1597855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects.
    Umemura K; Ikeda Y; Matsushima N; Kondo K
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):398-407. PubMed ID: 27652589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke.
    Conrado DJ; Gonzalez D; Derendorf H
    Ann N Y Acad Sci; 2010 Oct; 1207():134-42. PubMed ID: 20955436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
    Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
    J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and drug interactions--relevant factors for the choice of a drug.
    Zech K; Steinijans VW; Huber R; Kolassa N; Radtke HW
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S3-6. PubMed ID: 8793598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.